Healthcare
Paxman AB (publ)(PXMBF)
Live Price
Offline$3.50
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $1.18B
- Revenue Growth
- +23.5%
- EPS Growth
- -136.0%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Paxman AB (publ) (PXMBF) is a Healthcare stock with a market cap of $1.18B and listed on OTC. The stock last traded around $3.50 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +23.5%, EPS growth of -136.0%, a dividend yield of 0.0%. What stands out right now is revenue +23.5%, EPS -136.0%, free cash flow -153.0% with operating margin 1.5% and ROIC 1.1%. Valuation is more restrained than many high-expectation growth names at price/sales 3.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PXMBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+23.5% vs +7.6% peer median
Operating Margin
Below sector median
+1.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 21, 2026 with an EPS surprise of -94.3% and a revenue surprise of +1.5%.
The operating picture looks softer than before
Revenue is at +23.5% and EPS is at -136.0%, with operating margin around 1.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 21, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | -94.3% | +0.0% | +0.0% | โ |
2026 Feb 27, 2026 | -305.8% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PXMBF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PXMBF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PXMBF and SPY.
Company Overview
Paxman AB (publ)
Other OTC
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. Paxman AB (publ) was founded in 1996 and is based in Karlshamn, Sweden.
- Leadership
- Richard Paxman
- IPO Date
- Apr 23, 2019
- Employees
- 105
- Street Address
- Pirgatan 13
- Mailing
- Karlshamn, 374 35
- Region
- Karlshamn, SE
- Reporting Currency
- USD
- Investor Line
- +46 8 506 363 40
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 37.0
- Price/Sales
- 3.8
- Price/Book
- 2.9
Growth
- Revenue
- +23.5%
- EPS
- -136.0%
- Free Cash Flow
- -153.0%
Profitability
- Gross Margin
- 47.7%
- Operating Margin
- 1.5%
- Net Margin
- -5.1%
- ROE
- -4.2%
- ROIC
- 1.1%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 3.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.